SECOND SUPPLEMENTAL INDENTURESecond Supplemental Indenture • November 9th, 2020 • Verastem, Inc. • Pharmaceutical preparations • New York
SECOND SUPPLEMENTAL INDENTURE, dated as of [ ], 2020 (“Second Supplemental Indenture”), between Verastem, Inc., a Delaware corporation, as issuer (the “Company”), and Wilmington Trust, National Association, a national banking association, as trustee (the “Trustee”), supplementing the Indenture, dated as of October 17, 2018, between the Company and the Trustee (the “Base Indenture” and, as amended, modified and supplemented by this Second Supplemental Indenture, the “Indenture”).
ASSET PURCHASE AGREEMENT BY AND BETWEEN SECURA BIO, INC. (“PURCHASER”) and VERASTEM, INC. (“SELLER”) Dated as of August 10, 2020 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE...Asset Purchase Agreement • November 9th, 2020 • Verastem, Inc. • Pharmaceutical preparations
Exchange AgreementExchange Agreement • November 9th, 2020 • Verastem, Inc. • Pharmaceutical preparations • New York
The Old Notes were issued pursuant to that certain Indenture (the “2018 Indenture”) and First Supplemental Indenture (collectively, the “Existing Indenture”), each dated as of October 17, 2018, between the Company, as issuer, and Wilmington Trust, National Association, as trustee (in such capacity, the “Trustee”). The New Notes will be issued pursuant to the 2018 Indenture and a Second Supplemental Indenture dated as of the Closing Date (as defined below) (collectively, the “Indenture”) between the Company, as issuer, and the Trustee, substantially in the forms set forth as Exhibit D hereto.
